Corrigendum to “Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database” Eur J Cancer. 2023 Jan;178:162–170
Titel:
Corrigendum to “Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database” Eur J Cancer. 2023 Jan;178:162–170
Auteur:
Margalit, Ofer Harmsen, William S. Shacham-Shmueli, Einat Voss, Molly M. Boursi, Ben Wagner, Anna D. Cohen, Romain Olswold, Curtis L. Saltz, Leonard B. Goldstein, Daniel A. Hurwitz, Herbert Tebbutt, Niall C. Kabbinavar, Fairooz F. Adams, Richard A. Chibaudel, Benoist Grothey, Axel Yoshino, Takayuki Zalcberg, John de Gramont, Aimery Shi, Qian Lenz, Heinz-Josef